In8Bio, Inc. Stock Price, News & Analysis

IN8bio (NASDAQ: INAB) reported Q2 2024 financial results and corporate highlights. Key points include:

1. Presented 100% 1-year complete remission in evaluable patients with hematologic malignancies for INB-100 at EHA 2024.

2. Demonstrated 92% of glioblastoma patients treated with INB-200 exceeded median seven-month progression-free survival at ASCO 2024.

3. Showcased robust manufacturing platform for DeltEx gamma-delta T cells at ASGCT 2024.

4. Q2 2024 financials: R&D expenses increased to $5.2 million, net loss was $8.6 million ($0.19 per share), and cash position as of June 30, 2024, was $10.2 million.

IN8bio continues to advance its gamma-delta T cell therapies for solid and hematologic cancers, showing promising results in clinical trials.

IN8bio, a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, announced that its CEO and Co-founder, William Ho, will be participating in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference.

The event is scheduled for June 25, 2024, at 2:30 p.m. ET. The presentation will include a fireside chat, providing insights into IN8bio's advancements and future plans.

A live webcast and replay of the presentation will be accessible under the 'Events and Presentations' section on the IN8bio website.

IN8bio has released positive data from its Phase 1 trial of INB-100, demonstrating that 100% of evaluable leukemia patients (n=10) achieved durable complete remission at one year. The trial included high-risk and relapsed AML patients who failed multiple therapies, including CAR-T. Long-term in vivo expansion and persistence of gamma-delta T cells were observed, with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity reported. The trial has been expanded to enroll 10 more patients at the recommended Phase 2 dose. Updated data are expected in late 2024 and 2025, with plans to discuss a potential registrational trial with the FDA. One patient died of idiopathic pulmonary fibrosis, and two patients with TP53 mutations relapsed but remain alive.

IN8bio (Nasdaq: INAB) presented promising preliminary data of INB-200 for glioblastoma at the 2024 ASCO Annual Meeting. The Phase 1 study of INB-200 showed that 92% of patients surpassed the median progression-free survival (PFS) of 7 months achieved with the standard Stupp regimen, with a median follow-up of 11.7 months. Notably, one patient remained progression-free for nearly three years. The study involved 13 patients across three dosing regimens, revealing a favorable safety profile with no serious treatment-related adverse events. All patients completing the full treatment protocol exceeded the median PFS of 7 months, and radiologic evaluations indicated positive treatment effects. IN8bio is now progressing with a Phase 2 study to further evaluate the therapy.

IN8bio, a clinical-stage biopharmaceutical company listed on Nasdaq as INAB, announced its participation in the International Society for Cell & Gene Therapy (ISCT) 2024 from May 28 to June 1 in Vancouver, Canada. IN8bio will present multiple findings on their gamma-delta T cell therapies. Dr. Kate Rochlin, COO, emphasized the significance of these presentations in advancing their proprietary manufacturing platform. Highlights include the INB-400 DeltEx drug-resistant immunotherapy (DRI) multi-center clinical trial and analyses comparing healthy donor and patient-manufactured autologous DeltEx DRI products. These developments are poised to improve cancer patient outcomes by targeting and potentially eradicating cancer cells.

IN8bio announced the upcoming presentation of updated Phase 1 study results for INB-200 at the 2024 ASCO Annual Meeting. INB-200, an autologous Drug Resistant Immunotherapy (DeltEx DRI), is being evaluated as a first-line treatment for newly diagnosed glioblastoma multiforme (GBM). The study involved 23 patients and showed promising progression-free survival (PFS) rates beyond the median expected with standard treatment. There were no dose-limiting toxicities, although some patients experienced adverse events like decreased white blood cell count and fatigue. The presentation will take place on June 1, 2024.

IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced it will present updated interim results from their Phase 1 trial of INB-100 at the upcoming European Hematology Association (EHA) 2024 Congress in Madrid, June 13-16. INB-100 is a gamma-delta T cell therapy aimed at increasing survival and reducing cancer recurrence in leukemia patients post-haploidentical stem cell transplantation, without severe graft-versus-host disease. The presentation will be held on June 14, 2024, at 10:00 a.m. CEST by Dr. Joseph P. McGuirk. Abstracts are accessible on the EHA website, and the poster will be available on IN8bio's site following the session.

IN8bio presented details about its robust and reproducible gamma-delta T cell therapy manufacturing platform at ASGCT 2024. The data demonstrate significant advancements in the characterization of gamma-delta T cell-based therapies, showing increased potency, effector functions, and trafficking capabilities. The study evaluated T cell products from healthy donors and GBM patients, revealing consistent profiles and gene expression changes throughout the manufacturing process.

IN8bio, Inc. (Nasdaq: INAB) reported financial results for Q1 2024, highlighting progress in gamma-delta T cell programs. Key points include preclinical data on nsCAR platform targeting cancer cells, peer-reviewed publication on DeltEx Drug Resistant Immunotherapy for GBM, and dosing first patient in Phase 2 clinical trial. Financially, R&D expenses increased to $4.9 million, G&A expenses were $3.7 million, net loss was $8.6 million, and cash position stood at $13.0 million.